Episode 6: PD-L1 Prevalence - Reconciling clinical data with real world data

In episode number 6 of Agilent’s “Dialogues in CDx” podcast, we explore how to bridge the gap between clinical data and the realities of daily laboratory practice. To unpack this topic, we are joined by two distinguished experts who bring complementary perspectives from pathology and oncology.Dr. Birgit Guldhammer Skov, consultant pathologist at the Department of Pathology, Sjaelland University Hospital in Denmark, works primarily with lung cancer. She has been involved in evaluating PD-L1 in lung cancer since the biomarker was introduced in 2016. Our second guest, Professor Inge Marie Svane, is a consultant oncologist at the Department of Oncology at Herlev Hospital in Denmark and Director of the national “Center for Cancer Immune Therapy” (CCIT). She currently leads oncology care for melanoma patients in eastern Denmark and has a special interest in real-world data and new treatment strategies for anti-PD1 refractory patients.This podcast series is part of the educational resources supporting the PD-L1 IHC 22C3 pharmDx assay. For access to all episodes plus a wealth of additional PD-L1 education for pathologists, explore Agilent's ⁠⁠⁠⁠CDx Digital Education Portal⁠⁠⁠⁠ today.D0133061 _1.00